Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Recursion · Partnership · October 15, 2026

Sanofi exercised an option to advance a potential first-in-class small molecule candidate from its collaboration with Recursion. The drug is designed to target inflammatory diseases and is expected to enter Phase 1 clinical trials in 2027.

Read the announcement

AntSpace’s summary of Recursion’s own announcement: read the original.

More updates from Recursion